Equities

Atea Pharmaceuticals Inc

AVIR:NSQ

Atea Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.71
  • Today's Change-0.11 / -2.88%
  • Shares traded272.12k
  • 1 Year change+16.67%
  • Beta0.1753
Data delayed at least 15 minutes, as of Sep 20 2024 19:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform0
Hold1
Sell1
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Atea Pharmaceuticals Inc share price to rise to 6.88 in the next year from the last price of 3.82.
High80.1%6.88
Med80.1%6.88
Low80.1%6.88

Earnings history & estimates in USD

On Aug 07, 2024, Atea Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.48 per share. This result exceeded the -0.77 consensus loss of the 2 analysts covering the company and under-performed last year's 2nd quarter results by 41.18%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate-14.68%
Atea Pharmaceuticals Inc reported annual 2023 losses of -1.63 per share on Feb 28, 2024.
Average growth rate-17.27%
More ▼

Revenue history & estimates in USD

Atea Pharmaceuticals Inc did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Atea Pharmaceuticals Inc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate+174.16%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.